Rifapentine for the treatment of latent tuberculosis

References

• Global Tuberculosis Report 2015. Geneva: World Health Organization; 2015 [cited 2016 May 15]. Available from: http://www.who.int/tb/publications/global_report/en/.
   Google Scholar
• Greenberg SD, Frager D, Suster B, et al. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). Radiology. 1994;193:115–119.
   PubMed Web of Science ®Google Scholar
• Global tuberculosis report 2015. World Health Organization, Geneva; 2015 [cited 2016 May 22]. http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• CDC. Reported tuberculosis in the United States, 2010. Atlanta (GA): US Department of Health and Human Services, CDC; 2011 [cited 2016 Jun 30]. Available from: http://www.cdc.gov/tb/statistics/reports/2010/default.htm
   Google Scholar
• Raviglione MC, Snider DE Jr., Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220–226.
   PubMed Web of Science ®Google Scholar
• Taylor ZNC, Blumberg HM, for the American Thoracic Society; Centers for Disease Control and Prevention; and Infectious Diseases Society of America. Controlling Tuberculosis in the United States: Recommendations from the American Thoracic Society, CDC, and the InfectioDiseases Society of America. Morb Mortal Wkly Rep. 2005;54:1161.
   Google Scholar
• Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697–1703.
   PubMed Web of Science ®Google Scholar
• Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46:1563–1576.
   PubMed Web of Science ®Google Scholar
• Lin PL, Flynn JL. Understanding latent tuberculosis: a moving target. J Immunol. 2010;185:15–22.
   PubMed Web of Science ®Google Scholar
• Barry CE III, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol. 2009;7:845–855.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis control, 2009. Epidemiology, strategy, financing. Geneva: World Health Organization; 2009. WHO/HTM/TB/2009.411.
   Google Scholar
• Centers for Disease Control. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650–1653.
   PubMedGoogle Scholar
• Lwilla F, Schellenberg D, Masanja H, et al. Evaluation of efficacy of community-based vs. institutional-based direct observed short-course treatment for the control of tuberculosis in Kilombero district, Tanzania. Trop Med Int Health. 2003;8:204–210.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012;206:1030–1040.
   PubMed Web of Science ®Google Scholar
• Wade MM, Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis. Front Biosci. 2004;9:975–994.
   PubMed Web of Science ®Google Scholar
• Williams DL, Spring L, Collins L, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998;42:1853–1857.
   PubMed Web of Science ®Google Scholar
• Chan JG, Bai X, Traini D. An update on the use of rifapentine for tuberculosis therapy. Expert Opin Drug Deliv. 2014;11:421–431.
   PubMed Web of Science ®Google Scholar
• Williamson B, Dooley KE, Zhang Y, et al. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013;57:6366–6369.
   PubMed Web of Science ®Google Scholar
• Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother. 2008;52:4037–4042.
   PubMed Web of Science ®Google Scholar
• Regazzi M, Carvalho AC, Villani P, et al. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014;53:489–507.
   PubMed Web of Science ®Google Scholar
• Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clin Infect Dis. 2006;43:1468–1475.
   PubMed Web of Science ®Google Scholar
• Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA. 1998;279:943–948.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Fukami T, Kobayashi Y, et al. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol. 2011;82:1747–1756.
   PubMed Web of Science ®Google Scholar
• Keung AC, Eller MG, Weir SJ. Single-dose pharmacokinetics of rifapentine in women. J Pharmacokinet Biopharm. 1998;26:75–85.
   PubMedGoogle Scholar
• Weiner M, Bock N, Peloquin CA, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med. 2004;169:1191–1197.
   PubMed Web of Science ®Google Scholar
• Zvada SP, Van Der Walt JS, Smith PJ, et al. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother. 2010;54:3390–3394.
   PubMed Web of Science ®Google Scholar
• Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet. 1996;30:445–462.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989–1008.
   PubMed Web of Science ®Google Scholar
• Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17:432–437.
   PubMed Web of Science ®Google Scholar
• Grandison MK, Boudinot FD. Age-related changes in protein binding of drugs: implications for therapy. Clin Pharmacokinet. 2000;38:271–290.
   PubMed Web of Science ®Google Scholar
• Johnson JA, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol. 1997;51:485–488.
   PubMed Web of Science ®Google Scholar
• Reith K, Keung A, Toren PC, et al. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos. 1998;26:732–738.
   PubMed Web of Science ®Google Scholar
• Keung AC, Eller MG, Weir SJ. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J Clin Pharmacol. 1998;38:517–524.
   PubMed Web of Science ®Google Scholar
• Egelund EF, Weiner M, Singh RP, et al. Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2014;58:4904–4910.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther. 2012;91:881–888.
   PubMed Web of Science ®Google Scholar
• Savic RM, Lu Y, Bliven-Sizemore E, et al. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014;58:3035–3042.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Savic RM, Park JG, et al. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59:3399–3405.
   PubMed Web of Science ®Google Scholar
• Mitchison DA. Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. Int J Tuberc Lung Dis. 2012;16:1186–1189.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51:3781–3788.
   PubMed Web of Science ®Google Scholar
• Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother. 2003;47:2118–2124.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327–341.
   PubMed Web of Science ®Google Scholar
• Mor N, Simon B, Mezo N, et al. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agents Chemother. 1995;39:2073–2077.
   PubMed Web of Science ®Google Scholar
• Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis. 1981;123:367–371.
   PubMed Web of Science ®Google Scholar
• Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007;4:e344.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Goh KS, Berchel M, et al. Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother. 2000;46:565–570.
   PubMed Web of Science ®Google Scholar
• Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med. 2006;174:94–101.
   PubMed Web of Science ®Google Scholar
• Nuermberger E, Tyagi S, Williams KN, et al. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med. 2005;172:1452–1456.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang M, Rosenthal IM, et al. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2009;180:1151–1157.
   PubMed Web of Science ®Google Scholar
• Dutta NK, Illei PB, Peloquin CA, et al. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2012;56:3726–3731.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–2166.
   PubMed Web of Science ®Google Scholar
• Schechter M, Zajdenverg R, Falco G, et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med. 2006;173:922–926.
   PubMed Web of Science ®Google Scholar
• Martinson NA, Barnes GL, Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365:11–20.
   PubMed Web of Science ®Google Scholar
• Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015;169:247–255.
   PubMed Web of Science ®Google Scholar
• Weiner M, Savic RM, Kenzie WR, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with Rifapentine and isoniazid for latent tuberculosis infection. J Pediatric Infect Dis Soc. 2014;3:132–145.
   PubMedGoogle Scholar
• Cruz AT, Starke JR. Safety and adherence for 12 weekly doses of isoniazid and rifapentine for pediatric tuberculosis infection. Pediatr Infect Dis J. 2016;35:811–813.
   PubMed Web of Science ®Google Scholar
• Priftin [package insert]. In: Aventis S, editor. Bridgewater (NJ); 2014.
   Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174:935–952.
   PubMed Web of Science ®Google Scholar
• Bliven-Sizemore EE, Sterling TR, Shang N, et al. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015;19:1039–1044, i–v.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Moro RN, Borisov AS, et al. Flu-like and other systemic drug reactions among persons receiving weekly Rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61:527–535.
   PubMed Web of Science ®Google Scholar
• Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S440–450.
   PubMedGoogle Scholar
• Bliven-Sizemore EKA, Malone S, Weiner M, et al. CYP3A induction by rifampin and rifapentine: which drug and dose does it best? In: abstr O_04 Abstr. 4th International Workshop Clinical Pharmacology Tuberculosis Drugs; 2011 Sep 16; Chicago (IL).
   Google Scholar
• Winter H, Egizi E, Murray S, et al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015;59:1219–1224.
   PubMed Web of Science ®Google Scholar
• Zvada SP, Denti P, Geldenhuys H, et al. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrob Agents Chemother. 2012;56:4471–4473.
   PubMed Web of Science ®Google Scholar
• Cohn DL. Treatment of latent tuberculosis infection. Semin Respir Infect. 2003;18:249–262.
   PubMedGoogle Scholar
• Temple ME, Nahata MC. Rifapentine: its role in the treatment of tuberculosis. Ann Pharmacother. 1999;33:1203–1210.
   PubMed Web of Science ®Google Scholar
• Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother. 2014;69:1079–1085.
   PubMed Web of Science ®Google Scholar
• Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599–1608.
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, et al. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154–167.
   PubMed Web of Science ®Google Scholar
• Lau YY, Huang Y, Frassetto L, et al. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81:194–204.
   PubMed Web of Science ®Google Scholar
• Bidstrup TB, Stilling N, Damkier P, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol. 2004;60:109–114.
   PubMed Web of Science ®Google Scholar
• Podany AT, Bao Y, Swindells S, et al. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving Rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis. 2015;61:1322–1327.
   PubMed Web of Science ®Google Scholar
• Farenc C, Doroumian S, Cantalloube C, et al. Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir pharmacokinetics [poster P-H1]. Conference on retroviruses and opportunistic infections; 2014; Mar 3–6; Boston (MA).
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2015. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
   Google Scholar
• DeLuca A, Frick M, Lessem E, et al. Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations. Public Health Action. 2014;4:238–242.
   PubMedGoogle Scholar
• Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17:1531–1537.
   PubMed Web of Science ®Google Scholar
• Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis trials consortium. Lancet. 1999;353:1843–1847.
   PubMed Web of Science ®Google Scholar
• Prats E, Carril J, Herranz R, et al. A Spanish multicenter scintigraphic study of the breast using Tc 99m MIBI. Report of results. Rev Esp Med Nucl. 1998;17:338–350.
   PubMedGoogle Scholar
• Khan J, Malik A, Hussain H, et al. Tuberculosis diagnosis and treatment practices of private physicians in Karachi, Pakistan. East Mediterr Health J. 2003;9:769–775.
   PubMedGoogle Scholar